Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To determine the efficacy of the combination of imatinib mesylate and docetaxel in
recurrent or metastatic head and neck squamous cell cancer by serial measurements of
tumor response (extent, frequency, duration).
Secondary Objectives:
- To assess the safety and tolerability of imatinib mesylate and docetaxel in patients
with recurrent or metastatic head and neck squamous cell cancer.
- To explore the biologic effects of imatinib mesylate and docetaxel on tumor tissue by
immunohistochemical analysis of microvessel density and phosphorylation of
Platelet-derived growth factor receptors (PDGF-R).
- To explore the effects of imatinib mesylate and docetaxel on surrogate markers in serum.
- To assess the rate of survival.